Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amgen Inc. (AMGN : NSDQ)
 
 • Company Description   
Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Number of Employees: 31,500

 
 • Price / Volume Information   
Yesterday's Closing Price: $339.30 Daily Weekly Monthly
20 Day Moving Average: 2,821,843 shares
Shares Outstanding: 539.68 (millions)
Market Capitalization: $183,115.11 (millions)
Beta: 0.44
52 Week High: $391.29
52 Week Low: $267.83
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.67% -7.43%
12 Week -10.55% -17.31%
Year To Date 3.66% -5.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE AMGEN CENTER DRIVE
-
THOUSAND OAKS,CA 91320
USA		 ph: 805-447-1000
fax: 805-447-1010		 investor.relations@amgen.com http://www.amgen.com
 
 • General Corporate Information   
Officers
Robert A. Bradway - Chief Executive Officer; Chairman of the Board and
Peter H. Griffith - Executive Vice President andChief Financial Office
Matthew C. Busch - Vice President; Finance andChief Accounting Office
Wanda M. Austin - Director
Michael V. Drake - Director

Peer Information
Amgen Inc. (CORR.)
Amgen Inc. (RSPI)
Amgen Inc. (CGXP)
Amgen Inc. (BGEN)
Amgen Inc. (GTBP)
Amgen Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 031162100
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/04/26
Share - Related Items
Shares Outstanding: 539.68
Most Recent Split Date: 11.00 (2.00:1)
Beta: 0.44
Market Capitalization: $183,115.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.97%
Current Fiscal Quarter EPS Consensus Estimate: $5.60 Indicated Annual Dividend: $10.08
Current Fiscal Year EPS Consensus Estimate: $22.37 Payout Ratio: 0.46
Number of Estimates in the Fiscal Year Consensus: 15.00 Change In Payout Ratio: 0.01
Estmated Long-Term EPS Growth Rate: 4.45% Last Dividend Paid: 05/15/2026 - $2.52
Next EPS Report Date: 08/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 15.17
Trailing 12 Months: 15.35
PEG Ratio: 3.41
Price Ratios
Price/Book: 19.93
Price/Cash Flow: 10.04
Price / Sales: 4.92
EPS Growth
vs. Year Ago Period: 5.10%
vs. Previous Quarter: -2.65%
Sales Growth
vs. Year Ago Period: 5.76%
vs. Previous Quarter: -12.65%
ROE
03/31/26 - 137.41
12/31/25 - 148.37
09/30/25 - 162.59
ROA
03/31/26 - 13.28
12/31/25 - 13.23
09/30/25 - 13.18
Current Ratio
03/31/26 - 1.26
12/31/25 - 1.14
09/30/25 - 1.28
Quick Ratio
03/31/26 - 1.01
12/31/25 - 0.90
09/30/25 - 0.99
Operating Margin
03/31/26 - 32.21
12/31/25 - 32.21
09/30/25 - 32.92
Net Margin
03/31/26 - 20.96
12/31/25 - 20.98
09/30/25 - 19.47
Pre-Tax Margin
03/31/26 - 24.41
12/31/25 - 24.42
09/30/25 - 22.92
Book Value
03/31/26 - 17.03
12/31/25 - 16.08
09/30/25 - 17.86
Inventory Turnover
03/31/26 - 1.86
12/31/25 - 1.86
09/30/25 - 1.83
Debt-to-Equity
03/31/26 - 5.65
12/31/25 - 5.78
09/30/25 - 5.45
Debt-to-Capital
03/31/26 - 84.95
12/31/25 - 85.24
09/30/25 - 84.50
 

Powered by Zacks Investment Research ©